Cite
Huang D, Chowdhury S, Wang H, et al. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep Med. 2021;2(12):100471doi: 10.1016/j.xcrm.2021.100471.
Huang, D., Chowdhury, S., Wang, H., Savage, S. R., Ivey, R. G., Kennedy, J. J., Whiteaker, J. R., Lin, C., Hou, X., Oberg, A. L., Larson, M. C., Eskandari, N., Delisi, D. A., Gentile, S., Huntoon, C. J., Voytovich, U. J., Shire, Z. J., Yu, Q., Gygi, S. P., Hoofnagle, A. N., Herbert, Z. T., Lorentzen, T. D., Calinawan, A., Karnitz, L. M., Weroha, S. J., Kaufmann, S. H., Zhang, B., Wang, P., Birrer, M. J., & Paulovich, A. G. (2021). Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell reports. Medicine, 2(12), 100471. https://doi.org/10.1016/j.xcrm.2021.100471
Huang, Dongqing, et al. "Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer." Cell reports. Medicine vol. 2,12 (2021): 100471. doi: https://doi.org/10.1016/j.xcrm.2021.100471
Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, Hoofnagle AN, Herbert ZT, Lorentzen TD, Calinawan A, Karnitz LM, Weroha SJ, Kaufmann SH, Zhang B, Wang P, Birrer MJ, Paulovich AG. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep Med. 2021 Dec 21;2(12):100471. doi: 10.1016/j.xcrm.2021.100471. eCollection 2021 Dec 21. PMID: 35028612; PMCID: PMC8714940.
Copy
Download .nbib